Matthew Rabinowitz Sells $10.75 Million in Natera Shares

Matthew Rabinowitz, the Executive Chairman of Natera, Inc. (NasdaqGS: NTRA), sold 50,000 shares of the company on June 15, 2026. The transaction, which was part of a pre-planned trading arrangement, was valued at approximately $10.75 million, with the shares sold at an average price of $214.91 each.

Insider Buying and Selling at Natera, Inc.

In addition to Rabinowitz's recent sale, he also sold another 50,000 shares on June 12, 2026, at an average price of $214.03. Gail Boxer Marcus, another insider, sold 11,000 shares at $217.21 on June 5, 2026, but also bought the same amount at $22.83 earlier that day. CEO and President Steven Leonard Chapman sold 41,124 shares at $221.03 on June 4, 2026, under a planned sale.

Other Institutional Activity in Natera

Several major funds have adjusted their positions in Natera. JPMorgan Chase & Co. added 532,333 shares, bringing their total to 13,386,667 shares worth about $2.50 billion. Price T Rowe Associates increased its holdings by 1,312,887 shares, ending with 12,184,876 shares valued at approximately $2.44 billion. Conversely, BlackRock, Inc. reduced its position by 182,103 shares, holding 10,677,338 shares worth $2.14 billion. Vanguard Capital Management LLC and Vanguard Portfolio Management LLC both established new positions with shares totaling 6,008,496 and 5,644,695, respectively.

Natera, Inc. Stock Down 30.8%

Natera, Inc. is currently trading near $218.57. The company has a market cap of $31.07 billion and a beta of 1.544, indicating moderate volatility compared to the market. Its 52-week range spans from $131.81 to $256.36. The stock's 50-day moving average is $206.82, with a 200-day moving average of $205.71. Natera has a current ratio of 2.959 and a quick ratio of 2.697, while its debt-to-equity ratio stands at 13.533.

Recent Earnings

In its most recent earnings report, Natera recorded revenue of $2.50 billion, marking a growth of 38.8% from the previous year. However, the company is not yet profitable, with a net margin of -9.05% and a return on equity of -15.019%. The next earnings report is expected on August 6, 2026.

Analysts Set New Price Targets

On June 12, 2026, RBC Capital reinstated coverage of Natera with a "buy" rating and a price target of $275. Goldman Sachs initiated coverage on June 5, 2026, with a "hold" rating and a $245 target. Wolfe Research assumed coverage on June 2, 2026, giving a "buy" rating and a $260 target. The consensus among 20 analysts is a "buy" rating, with a mean price target of $260.05.

About Natera, Inc.

Natera, Inc. is a diagnostics company headquartered in Austin, Texas, specializing in molecular testing services. It offers a range of tests, including Signatera for cancer monitoring, Panorama for prenatal screening, and Prospera for organ transplant assessment. The company was founded in 2003 and is led by CEO Steven Leonard Chapman. Natera employs over 6,000 people and collaborates with various partners to develop and commercialize genetic testing assays.

Bottom Line

Matthew Rabinowitz's recent sale of Natera shares highlights insider activity within the company. Natera is a key player in the diagnostics industry, with significant institutional interest and analyst coverage. Investors often track such insider transactions for potential insights, though it's important to remember that these filings reflect past actions and not necessarily current positions.